Iskalni niz je ali predolg ali pa vsebuje preveč besed.
Prevodi: sl > en
1–13/13
in vitro meso
1 Prevajalska redakcija
RS
EMEA
Ugotovitve študij in vitro kažejo, da lamotrigin ne izpodriva drugih antiepileptikov z beljakovinskih vezavnih mest.
Evidence from in vitro studies indicates that lamotrigine does not displace other AEDs from protein binding sites.
2 Prevajalska redakcija
RS
EMEA
Nadalje se je za levetiracetam v in vitro študijah pokazalo, da se veže na specifično mesto v možganskem tkivu glodalcev.
Furthermore, levetiracetam has been shown in in vitro studies to bind to a specific site in rodent brain tissue.
3 Prevajalska redakcija
RS
EMEA
V in vitro študijah druga zdravila niso izpodrivala enfurvitida z njegovih vezalnih mest, in tudi enfuvirtid ni izpodrival drugih zdravil z njihovih vezalnih mest.
In in vitro studies, enfuvirtide was not displaced from its binding sites by other medicinal products, nor did enfuvirtide displace other medicinal products from their binding sites.
4 Prevajalska redakcija
RS
EMEA
In vitro študije so pokazale, da se odpornost proti ciprofloksacinu razvije postopno in je pogosto posledica mutacij na ciljnih mestih DNK giraze in topoizomeraze IV.
In-vitro resistance to ciprofloxacin can be acquired through a stepwise process by target site mutations in both DNA gyrase and topoisomerase IV.
5 Prevajalska redakcija
RS
EMEA
V preskusih in vitro, vključno z vezavo na receptorska mesta za insulin in IGF- 1 ter učinki na celično rast, se je insulin aspart obnašal zelo podobno humanemu insulinu.
In in vitro tests, including binding to insulin and IGF-1 receptor sites and effects on cell growth, insulin aspart behaved in a manner that closely resembled human insulin.
6 Prevajalska redakcija
RS
EMEA
Raziskave in vitro in in vivo so pokazale, da pri izpostavitvi glive Aspergillus kaspofunginu pride do lize in odmrtja apikalnih vršičkov in mest vejanja hif, kjer se odvijata celična rast in delitev.
Studies in vitro and in vivo demonstrate that exposure of Aspergillus to caspofungin results in lysis and death of hyphal apical tips and branch points where cell growth and division occur.
7 Prevajalska redakcija
RS
EMEA
Dokazano je, da ibuprofen v in vitro pogojih izpodriva bilirubin iz vezavnega mesta na albuminih, zato je pri nedonošenčkih povečana nevarnost bilirubinske encefalopatije (glej poglavje 5. 2).
Since ibuprofen was shown in vitro to displace bilirubin from its binding site to albumin, the risk of bilirubin encephalopathy in premature newborn infants may be increased (see section 5.2).
8 Prevajalska redakcija
RS
EMEA
Odpornost na emtricitabin ali tenofovir je bila opažena in vitro in pri nekaterih bolnikih, okuženih z virusom HIV- 1, zaradi razvoja substitucije na RT na mestu M184V ali M184I pri emtricitabinu in substitucije na RT na mestu K65R pri tenofovirju.
Resistance to emtricitabine or tenofovir has been seen in vitro and in some HIV-1 infected patients due to the development of an M184V or M184I substitution in RT with emtricitabine or a K65R substitution in RT with tenofovir.
9 Prevajalska redakcija
RS
EMEA
V in vitro raziskavah se je pokazalo, da lahko ceftriakson izpodrine bilirubin z njegovega vezavnega mesta na serumskem albuminu, tako da bi pri takih bolnikih lahko prišlo do razvoja bilirubinske encefalopatije.
In vitro studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin and bilirubin encephalopathy can possibly develop in these patients.
10 Prevajalska redakcija
RS
EMEA
Vezava na proteine: čeprav se tolkapon v veliki meri veže na proteine, so in vitro študije pokazale, da pri terapevtskih koncentracijah ne spodriva varfarina, tolbutamida, digitoksina in fenitoina iz njihovih vezalnih mest.
Protein binding: Although tolcapone is highly protein bound, in vitro studies have shown that tolcapone did not displace warfarin, tolbutamide, digitoxin and phenytoin from their binding sites at therapeutic concentrations.
11 Prevajalska redakcija
RS
EMEA
Študije in vitro z radioaktivno označenim gabapentinom so pokazale novo peptidno vezavno mesto v tkivu podganjih možganov, vključno z neokorteksom in hipokampusom, ki je morda povezano z antikonvulzivnim in analgetičnim delovanjem gabapentina in njegovih strukturnih izpeljank.
In vitro studies with radiolabeled gabapentin have characterized a novel peptide binding site in rat brain tissues including neocortex and hippocampus that may relate to anticonvulsant and analgesic activity of gabapentin and its structural derivatives.
12 Prevajalska redakcija
RS
EMEA
Pri bolnikih z neovaskularno obliko SDM so bile po enkrat mesečni intravitrealni aplikaciji zdravila Lucentis koncentracije ranibizumaba v serumu večinoma nizke. Najvišja koncentracija (Cmax) je bila večinoma nižja od tiste koncentracije ranibizumaba, ki je potrebna za zaviranje biološke aktivnosti VEGF za 50 % (11- 27 ng/ ml po oceni testa celične proliferacije in vitro).
Following monthly intravitreal administration of Lucentis to patients with neovascular AMD, serum concentrations of ranibizumab were generally low, with maximum levels (Cmax) generally below the ranibizumab concentration necessary to inhibit the biological activity of VEGF by 50 % (11-27 ng/ ml, as assessed in an in vitro cellular proliferation assay).
13 Prevajalska redakcija
RS
EMEA
In vitro se fondaparinuks v veliki meri in specifično veže na antitrombinski protein z deležem vezave, ki je v smislu odvisnosti od odmerka odvisna od koncentracije v plazmi (98, 6 % do 97, 0 % v razponu koncentracije od 0, 5 do 2 mg/ l). lje Fondaparinuks se ne veže pomembno na druge proteine plazme, vključno s faktorjem 4 (PF4). vo Fondaparinuks se ne veže pomembno na proteine plazme, razen na ATIII, zato ni pričakovati medsebojnega delovanja z drugimi zdravili zaradi izpodrivanja z vezavnih mest na proteinih. do
In vitro, fondaparinux is highly and specifically bound to antithrombin protein with a dose-dependant plasma concentration binding d (98.6 % to 97.0 % in the concentration range from 0.5 to 2 mg/ l). Fondaparinux does not bind e significantly to other plasma proteins, including platelet factor 4 (PF4). ris Since fondaparinux does not bind significantly to plasma proteins other than ATIII, no interaction with other medicinal products by protein binding displacement are expected.
Prevodi: sl > en
1–13/13
in vitro meso